Try our beta test site
7 studies found for:    EZH2 | Lymphoma OR CLL
Show Display Options
Rank Status Study
1 Recruiting A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
Condition: B-Cell Lymphoma
Intervention: Drug: CPI-1205
2 Recruiting An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas
Conditions: B-cell Lymphomas (Phase 1);   Advanced Solid Tumors (Phase 1);   Diffuse Large B-cell Lymphoma (Phase 2);   Follicular Lymphoma (Phase 2);   Transformed Follicular Lymphoma;   Primary Mediastinal Large B-Cell Lymphoma
Intervention: Drug: EPZ-6438
3 Recruiting A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
Condition: Cancer
Intervention: Drug: GSK2816126
4 Not yet recruiting Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects
Conditions: Diffuse Large B Cell Lymphoma;   Primary Mediastinal Lymphoma;   Mantle Cell Lymphoma
Interventions: Drug: Tazemetostat;   Drug: Fluconazole;   Drug: Omeprazole;   Drug: Repaglinide
5 Recruiting Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Condition: Diffuse Large B-cell Lymphoma (DLBCL)
Intervention: Drug: MAK683
6 Not yet recruiting An Open-Label, Single-Center, Two-Part, Phase 1 Study to Characterize the Pharmacokinetics of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the Absorption, Distribution, Metabolism and Elimination of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas
Conditions: Diffuse Large B Cell Lymphoma;   Primary Mediastinal Lymphoma;   Mantle-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma
Intervention: Drug: Tazemetostat and [14C] Tazemetostat
7 Recruiting Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study
Conditions: Diffuse Large B-cell Lymphoma;   Follicular Lymphoma;   Malignant Rhabdoid Tumors (MRT);   Rhabdoid Tumors of the Kidney (RTK);   Atypical Teratoid Rhabdoid Tumors (ATRT);   Synovial Sarcoma;   Epitheliod Sarcoma;   Mesothelioma;   Advanced Solid Tumors
Intervention: Drug: Tazemetostat

Study has passed its completion date and status has not been verified in more than two years.